MDMA辅助治疗边缘型人格障碍。

Focus (American Psychiatric Publishing) Pub Date : 2022-10-01 Epub Date: 2022-10-25 DOI:10.1176/appi.focus.20220056
Jenna M Traynor, Daniel E Roberts, Stephen Ross, Richard Zeifman, Lois Choi-Kain
{"title":"MDMA辅助治疗边缘型人格障碍。","authors":"Jenna M Traynor, Daniel E Roberts, Stephen Ross, Richard Zeifman, Lois Choi-Kain","doi":"10.1176/appi.focus.20220056","DOIUrl":null,"url":null,"abstract":"<p><p>Borderline personality disorder is a complex psychiatric disorder with limited treatment options that are associated with large heterogeneity in treatment response and high rates of dropout. New or complementary treatments for borderline personality disorder are needed that may be able to bolster treatment outcomes. In this review, the authors comment on the plausibility for research on 3,4-methylenedioxymethamphetamine (MDMA) used in conjunction with psychotherapy for borderline personality disorder (i.e., MDMA-assisted psychotherapy [MDMA-AP]). On the basis of the promise of MDMA-AP in treating disorders overlapping with borderline personality disorder (e.g., posttraumatic stress disorder), the authors speculate on initial treatment targets and hypothesized mechanisms of change that are grounded in prior literature and theory. Initial considerations for designing MDMA-AP clinical trials to investigate the safety, feasibility, and preliminary effects of MDMA-AP for borderline personality disorder are also presented.</p>","PeriodicalId":73036,"journal":{"name":"Focus (American Psychiatric Publishing)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187385/pdf/","citationCount":"0","resultStr":"{\"title\":\"MDMA-Assisted Psychotherapy for Borderline Personality Disorder.\",\"authors\":\"Jenna M Traynor, Daniel E Roberts, Stephen Ross, Richard Zeifman, Lois Choi-Kain\",\"doi\":\"10.1176/appi.focus.20220056\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Borderline personality disorder is a complex psychiatric disorder with limited treatment options that are associated with large heterogeneity in treatment response and high rates of dropout. New or complementary treatments for borderline personality disorder are needed that may be able to bolster treatment outcomes. In this review, the authors comment on the plausibility for research on 3,4-methylenedioxymethamphetamine (MDMA) used in conjunction with psychotherapy for borderline personality disorder (i.e., MDMA-assisted psychotherapy [MDMA-AP]). On the basis of the promise of MDMA-AP in treating disorders overlapping with borderline personality disorder (e.g., posttraumatic stress disorder), the authors speculate on initial treatment targets and hypothesized mechanisms of change that are grounded in prior literature and theory. Initial considerations for designing MDMA-AP clinical trials to investigate the safety, feasibility, and preliminary effects of MDMA-AP for borderline personality disorder are also presented.</p>\",\"PeriodicalId\":73036,\"journal\":{\"name\":\"Focus (American Psychiatric Publishing)\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187385/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Focus (American Psychiatric Publishing)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1176/appi.focus.20220056\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/10/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Focus (American Psychiatric Publishing)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1176/appi.focus.20220056","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/10/25 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

边缘型人格障碍是一种复杂的精神障碍,治疗选择有限,与治疗反应的巨大异质性和高辍学率有关。需要对边缘型人格障碍进行新的或补充的治疗,以提高治疗效果。在这篇综述中,作者评论了3,4-亚甲二氧基甲基苯丙胺(MDMA)与边缘型人格障碍的心理治疗(即MDMA辅助心理治疗[MMDA-AP])结合使用的研究的合理性。基于MDMA-AP在治疗与边缘型人格障碍重叠的障碍(如创伤后应激障碍)方面的前景,作者推测了基于先前文献和理论的初始治疗靶点和假设的变化机制。还介绍了设计MDMA-AP临床试验以研究MDMA-AP治疗边缘型人格障碍的安全性、可行性和初步效果的初步考虑因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
MDMA-Assisted Psychotherapy for Borderline Personality Disorder.

Borderline personality disorder is a complex psychiatric disorder with limited treatment options that are associated with large heterogeneity in treatment response and high rates of dropout. New or complementary treatments for borderline personality disorder are needed that may be able to bolster treatment outcomes. In this review, the authors comment on the plausibility for research on 3,4-methylenedioxymethamphetamine (MDMA) used in conjunction with psychotherapy for borderline personality disorder (i.e., MDMA-assisted psychotherapy [MDMA-AP]). On the basis of the promise of MDMA-AP in treating disorders overlapping with borderline personality disorder (e.g., posttraumatic stress disorder), the authors speculate on initial treatment targets and hypothesized mechanisms of change that are grounded in prior literature and theory. Initial considerations for designing MDMA-AP clinical trials to investigate the safety, feasibility, and preliminary effects of MDMA-AP for borderline personality disorder are also presented.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信